Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) - Aix-Marseille Université Access content directly
Journal Articles ESMO Open Year : 2022

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

O. Mir
  • Function : Author
F. Bertucci
B. Narciso
  • Function : Author
C. Perrin
  • Function : Author
J.Y. Blay
E. Bompas
  • Function : Author

Abstract

Background: Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort.Patients and methods: All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software.Results: Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P < 0.001). Concerning cohort 1, young age, surgery of the primary tumor, and single metastatic site were independent favorable prognostic factors for OS. In cohort 2, surgery within an expert French Sarcoma Group center, absence of chemotherapy in the perioperative setting, the lungs as a single metastatic site, time to first metastasis >12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors.Conclusions: The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting.

Domains

Cancer
Fichier principal
Vignette du fichier
main.pdf (551.51 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03623511 , version 1 (03-06-2022)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

C. Moreau-Bachelard, L. Campion, M. Toulmonde, A. Le Cesne, M. Brahmi, et al.. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). ESMO Open, 2022, 7 (2), pp.100402. ⟨10.1016/j.esmoop.2022.100402⟩. ⟨hal-03623511⟩
91 View
41 Download

Altmetric

Share

Gmail Facebook X LinkedIn More